President Biden established the National Biotechnology and Biomanufacturing Initiative to drive research and development to “Solve Our Greatest Challenges.” The Initiative’s goals strongly suggest more non-dilutive funding opportunities in grants for R&D as well as contracts related to bioproducts and biomanufacturing.
SBIR/STTR programs could expire Sept 30. Reauthorization opposed by Rand Paul and others. SBIR/STTR grants enable commercialization of federally funded research and have broad benefits that improve life for all Americans as well as billions around the globe.
President Biden established the National Biotechnology and Biomanufacturing Initiative to drive research and development to “Solve Our Greatest Challenges.” The Initiative’s goals strongly suggest more non-dilutive funding opportunities in grants for R&D as well as contracts related to bioproducts and biomanufacturing.
Since venture investment in life science companies began to slump in 2021, biopharma companies have tightened their belts notch by notch to squeeze more utility from each cent and extend their runways. In this environment, non-dilutive funding has become ever more important, especially for small and mid-sized companies.
BioPharm America, where innovators partner to fuel the future of drug development.
The BioForward conference is designed to help life science companies connect with the best service providers. Each R&D company receives first ticket free. 10% off other tickets using our code…
Each $1 of non-dilutive funding from NIH translates into $8.38 of private sector investment in R&D. Companies which win non-dilutive funding from organizations such as BARDA, NIH, NSF, and CDMRP, are more likely to receive major equity investments.
BioFuture is a two-day, forward looking business development and investor conference designed to drive an engaging dialogue about the transformational changes taking place in the healthcare ecosystem. The conference will include plenary sessions, workshops, company presentations, investor meetings, one-on-one partnering meetings, and exhibits.
The HEALTHTECH INVESTMENT FORUM will focus on DIGITAL HEALTH, MEDTECH & DEVICES. The BIOTECH IN EUROPE FORUM is devoted to GLOBAL PARTNERING & INVESTMENT.
Advanced Therapies Europe will educate and inspire cell and gene therapy professionals in Europe, and those who wish to enter into the European market.